Seer, Inc. SEER

Technology SIC 3826 - Laboratory Analytical Instruments Nasdaq

Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health. Through our product, the Proteograph® Product Suite (Proteograph), we provide researchers with unbiased, deep, rapid and large-scale access to the proteome, enabling biological discovery that has historically been impractical. With our pioneering proprietary engineered nanoparticle (NP) technology and the Proteograph Product Suite, we provide the most complete, precise, and scalable platform for deep, unbiased proteomics to power population-scale studies and data-driven biology.

Proteins are the functional drivers of biology and the primary targets of most approved drugs. Unlike DNA, which is largely static over an individual's lifetime, the proteome is dynamic, reflecting real-time biological processes, disease states, and responses to therapeutic intervention. However, the molecular diversity of the proteome, arising from transcription, RNA processing, translation, post-translational modifications (PTMs), and protein–protein interactions, has historically limited researchers' ability to comprehensively characterize protein biology at scale. Traditional proteomic approaches have forced researchers to choose between depth and throughput: unbiased methods that lack scalability, or scalable methods that are targeted, epitope-dependent, and unable to resolve protein variants with sufficient precision.

Last close 1.95 2026-09-04
Market cap $108.0M 2026-06-30 share count
52-week range 1.55 - 2.41

Valuation FY2025 figures against the last close

P/S6.5x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $16.6M$14.2M$16.7M$15.5M$6.6M$656.0K
Cost of revenue $8.1M$7.1M$8.2M$8.4M$3.2M$0
Gross profit $8.5M$7.1M$8.5M$7.1M$3.4M$656.0K
R&D $43.9M$50.6M$53.0M$45.8M$29.1M$18.9M
SG&A $42.6M$56.6M$59.0M$58.5M$45.8M$15.4M
Total operating expenses $86.5M$107.2M$112.0M$104.3M$74.9M$34.3M
Operating income -$78.0M-$100.1M-$103.5M-$97.2M-$71.5M-$33.6M
Interest expense $0$22.0K$0
Pre-tax income -$73.4M-$86.5M-$86.3M-$93.0M-$71.2M-$32.8M
Income tax $201.0K$98.0K$0$0$0$0
Net income -$73.6M-$86.6M-$86.3M-$93.0M-$71.2M-$32.8M
EPS, basic -1.35-1.49-1.17-2.48
EPS, diluted -1.35-1.49-1.17-2.48
Shares, diluted (wtd. avg.) $63.9M$62.4M$60.9M$13.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $47.3M$40.8M$33.0M$53.7M$233.3M$333.9M$17.8M
Short-term investments $138.6M$195.7M$283.7M$368.0M$167.3M$98.3M
Receivables $4.3M$2.5M$0
Inventory $7.8M$7.4M$4.5M$4.6M$4.1M$551.0K
Total current assets $201.5M$253.3M$330.5M$435.0M$411.7M$433.1M
Property, plant and equipment $14.8M$18.6M$22.2M$19.4M$13.1M$8.4M
Total assets $296.1M$366.6M$436.3M$487.9M$539.1M$442.3M
Total current liabilities $15.7M$15.3M$13.2M$12.6M$13.4M$8.1M
Total liabilities $36.8M$39.0M$39.4M$40.9M$36.2M$10.7M
Retained earnings -$466.0M-$392.4M-$305.8M-$219.5M-$126.5M-$55.4M
Total equity $259.3M$327.6M$396.9M$447.0M$502.9M$431.6M$87.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$44.4M-$46.1M-$59.1M-$60.8M-$46.3M-$20.8M
Depreciation and amortisation $6.1M$6.2M$5.6M$3.9M$2.6M$1.6M
Stock-based compensation $15.4M$28.2M$34.4M$33.7M$25.9M$7.3M
Capital expenditure $1.8M$3.6M$7.3M$10.3M$6.9M$4.5M
Investing cash flow $61.5M$65.9M$37.9M-$122.7M-$170.9M-$34.6M
Financing cash flow -$10.6M-$11.5M$452.0K$3.9M$116.6M$371.5M
Buybacks $0$13.0K$20.0K$35.0K$13.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-255770.

Others in SIC 3826

TickerCompanyMarket capP/ERevenue growth
A AGILENT TECHNOLOGIES, INC. $42.53B 33.0x 6.7%
WAT WATERS CORP /DE/ $40.22B 38.0x 7.0%
ILMN ILLUMINA, INC. $32.95B 40.0x -0.7%
MTD METTLER TOLEDO INTERNATIONAL INC/ $26.95B 32.0x 4.0%
RVTY REVVITY, INC. $14.53B 62.9x 3.7%
BIO BIO-RAD LABORATORIES, INC. $10.33B 13.9x 0.7%
AVTR Avantor, Inc. $10.22B -3.4%
BRKR BRUKER CORP $8.88B 2.1%